Elsevier

Neuroscience

Volume 100, Issue 4, 11 October 2000, Pages 681-684
Neuroscience

Letter to Neuroscience
Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex—a possible mechanism of neuroprotection in major depression?

https://doi.org/10.1016/S0306-4522(00)00390-0Get rights and content

Abstract

Antidepressant drugs have been used for decades, but the neurobiological substrate of their efficacy is not completely understood. Although these drugs have well-established effects on monoamines, evidence is emerging that they may also affect other neurotransmitter systems. It has been shown that treatment with a wide range of antidepressants changes the binding characteristics of the N-methyl-d-aspartate type of glutamate receptor.23 This change is delayed and occurs only in the cortex. The mechanism that triggers it is unknown. We hypothesized that N-methyl-d-aspartate receptor alterations may be due to changes in the dynamics of cortical excitatory amino acid release. Such changes are of particular interest in areas such as the prefrontal cortex, a region involved in stress responses and affected in major depression.6 We investigated the effects of two antidepressants with different modes of action, imipramine and phenelzine, on glutamate and aspartate outflow in rat prefrontal cortex and striatum. We showed that antidepressants significantly decreased stimulated glutamate outflow. The effect had a rapid onset, was sustained during chronic administration and was only seen in the prefrontal cortex. This change may initiate receptor alterations. Furthermore, if antidepressants can dampen states of hyperglutamatergic activity and the subsequent excitotoxicity, their chronic use may have a considerable neuroprotective potential in major depression.

Section snippets

Materials

l-Glutamate, l-aspartate and β-mercaptoethanol were from Sigma (Poole, UK). Acetonitrile, sodium acetate trihydrate and di-sodium tetraborate were purchased from B.D.H. Laboratory Supplies (Lutterworth, Leicestershire, UK). o-Phthalaldehyde was from Aldrich (Gillingham, Dorset, UK).

Amino acid outflow in slices

Male Wistar rats (200–250 g) were used throughout. All efforts were made to minimize the number of animals used, and experiments were carried out in conformity with the 1986 UK Animals (Scientific Procedures) Act. For

References (26)

  • R Trullas et al.

    Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

    Eur. J. Pharmac.

    (1990)
  • Y Watanabe et al.

    Tianeptine attenuates stress-induced morphological changes in the hippocampus

    Eur. J. Pharmac.

    (1992)
  • Baldessarini R. J. (1996) Drugs and the treatment of psychiatric disorders: depression and mania. In Goodman and...
  • Cited by (105)

    • Alterations of cerebral glutamate in the euthymic state of patients with bipolar disorder

      2015, Psychiatry Research - Neuroimaging
      Citation Excerpt :

      Glutamate, on the other hand, as well as glutamatergic neurotransmission with a predomination of neurons/synapses in brain areas such as the hippocampus, prefrontal cortex, ACC and amygdala are linked by maladaptive synaptic excitability and plasticity to the genesis of mood disorders (Sanacora et al., 2012; Musazzi et al., 2013). This theory is supported by the finding that antidepressants partly reverse changes in glutamatergic synaptic levels (Michael-Titus et al., 2000; Pittaluga et al., 2007; Musazzi et al., 2013), and by effective antidepressant treatment with the NMDA receptor antagonist ketamine (Berman et al., 2000; Zarate et al., 2006). With our findings of increased glutamate concentration in the ACC, we support the theory of a hyperglutamatergic state or glutamatergic overactivity as a potential pathophysiological mechanism in bipolar disorder.

    • An update on amine oxidase inhibitors: Multifaceted drugs

      2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry
    View all citing articles on Scopus
    View full text